Citi reiterates Buy rating on SLB stock with $46 price target

SLB has seen an 8% stock decline over the past week, nearing its 52-week low, attributed to investor concerns over a conservative Q4 EBITDA forecast and recent downward earnings revisions. Despite this, multiple firms including Citi, Stifel, Jefferies, and BofA have reiterated Buy ratings, with Citi maintaining a $46 price target, asserting that the negative revision cycle is nearing its end and the stock is undervalued at 6.6 times its 2026 EBITDA estimate and a 10% free cash flow yield. This positive outlook is further bolstered by SLB's recent Q2 2025 earnings beat and anticipated $400 million in annual synergies from the ChampionX acquisition.

Analysis

Despite Schlumberger's (SLB) stock declining 8% in the past week to a near 52-week low of $33.32, a consensus of sell-side analysts including Citi, Stifel, Jefferies, and BofA Securities maintains a bullish outlook. The negative market reaction is attributed to investors pricing in a weaker fourth quarter, driven by a conservative second-half forecast from management and downward earnings revisions from 13 analysts. However, Citi contends this negative revision cycle is nearing its end and highlights the stock's valuation as attractive, trading at approximately 6.6 times the firm's 2026 EBITDA estimate and offering a roughly 10% free cash flow yield. This positive thesis is supported by SLB's recent modest Q2 2025 earnings beat, with an EPS of $0.74 and revenue of $8.55 billion, slightly exceeding forecasts. Furthermore, the completed acquisition of ChampionX is a key strategic catalyst, expected to generate $400 million in annual pre-tax synergies, which analysts believe will help resume EBITDA growth in the coming year.

Key Decisions for Investors

• Investors should consider the significant disconnect between the stock's recent decline to a 52-week low and the strong, reiterated 'Buy' ratings from multiple analyst firms, which may present a contrarian value opportunity.
• The successful integration of ChampionX and the realization of its projected $400 million in annual synergies are critical catalysts to monitor, as they are central to the analyst case for renewed EBITDA growth.
• Given the market's priced-in concerns, any positive updates to company guidance or signs that the negative earnings revision cycle has definitively concluded could serve as a major inflection point for the stock.
• The valuation metrics, particularly the ~10% free cash flow yield and the price targets from Citi ($46), Stifel ($52), and Jefferies ($53), offer a quantitative basis for assessing the potential upside from the current trading price.